A Phase 1 interventional study of High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed and 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-05.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin, linagliptin \& metformin extended release (XR) and the single tablets of empagliflozin, linagliptin and metformin XR administered simultaneously.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Use of adequate , e.g. any of the following methods plus condom: implants, injectables, combined oral or vaginal contraceptives, intrauterine device Sexually abstinent A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment) Surgically sterilised (including hysterectomy) , defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous levels of follicle-stimulating hormone above 40 U/L and estradiol below 30 ng/L is confirmatory)
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
Drug: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed · Drug: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions
Drug: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted · Drug: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
Drug: Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed · Drug: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)
Area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz) is presented. Plasma concentrations and/or parameters of a subject were considered as non-evaluable, if for example * The subject experienced emesis that occurred at or before 2 times median tmax of the respective treatment (median tmax was to be determined excluding the subject's experiencing emesis) * A pre-dose concentration was \>5% of the Cmax value measured in that subject * Missing samples or concentration data at important phases of PK disposition curve
Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)
Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz) is presented
Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Maximum Measured Concentration of Empagliflozin in Plasma (Cmax)
Maximum measured concentration of Empagliflozin in plasma (Cmax) is presented
Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Maximum Measured Concentration of Metformin in Plasma (Cmax)
Maximum measured concentration of Metformin in plasma (Cmax) is presented
Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Maximum Measured Concentration of Linagliptin in Plasma (Cmax)
Maximum measured concentration of Linagliptin in plasma (Cmax) is presented
Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)
Area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72) is presented
Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Area under the concentration-time curve of the Empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented
Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Area under the concentration-time curve of the Metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented
Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Area under the concentration-time curve of the Linagliptin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented
Time frame: 1.5 hours (h) before drug administration and 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h,10h, 12h, 24h, 34h, 48h, and 72h after drug administration
| Milestone | FDC 25 Fed (T1)/ E25+L5+M1000 Fed (R1) (Part 1) | E25+L5+M1000 Fed (R1)/ FDC 25 Fed (T1) (Part 1) | FDC 25 Fast (T2)/ E25+L5+M1000 Fast (R2) (Part 2) | E25+L5+M1000 Fast (R2)/ FDC 25 Fast (T2) (Part 2) | FDC 10 Fed (T3)/ E10+L5+M1000 Fed (R3) (Part 3) | E10+L5+M1000 Fed (R3)/ FDC 10 Fed (T3) (Part 3) |
|---|---|---|---|---|---|---|
| Started | 7 | 8 | 10 | 10 | 7 | 8 |
| Completed | 6 | 8 | 8 | 10 | 7 | 7 |
| Not completed | 1 | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Other than specified | 1 | 0 | 1 | 0 | 0 | 0 |
Area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz) is presented. Plasma concentrations and/or parameters of a subject were considered as non-evaluable, if for example * The subject experienced emesis that occurred at or before 2 times median tmax of the respective treatment (median tmax was to be determined excluding the subject's experiencing emesis) * A pre-dose concentration was \>5% of the Cmax value measured in that subject * Missing samples or concentration data at important phases of PK disposition curve
| nanomoles (nmol)*hours (h)/litres (L) | FDC 25 Fed (T1) | E25+L5+M1000 Fed (R1) | FDC 25 Fast (T2) | E25+L5+M1000 Fast (R2) | FDC 10 Fed (T3) | E10+L5+M1000 Fed (R3) |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz) | 5990 ± 25.6 | 6120 ± 22.8 | 6430 ± 20.2 | 6250 ± 18.7 | 2080 ± 15.4 | 2130 ± 15.5 |
Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz) is presented
| nanograms (ng)*h/ milliliter (mL) | FDC 25 Fed (T1) | E25+L5+M1000 Fed (R1) | FDC 25 Fast (T2) | E25+L5+M1000 Fast (R2) | FDC 10 Fed (T3) | E10+L5+M1000 Fed (R3) |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz) | 13900 ± 29.6 | 13900 ± 30.9 | 7920 ± 31.3 | 8260 ± 33.4 | 12000 ± 26.0 | 12200 ± 25.9 |
Maximum measured concentration of Empagliflozin in plasma (Cmax) is presented
| nmol/L | FDC 25 Fed (T1) | E25+L5+M1000 Fed (R1) | FDC 25 Fast (T2) | E25+L5+M1000 Fast (R2) | FDC 10 Fed (T3) | E10+L5+M1000 Fed (R3) |
|---|---|---|---|---|---|---|
| Maximum Measured Concentration of Empagliflozin in Plasma (Cmax) | 594 ± 17.7 | 630 ± 20.4 | 872 ± 24.5 | 817 ± 31.5 | 232 ± 20.5 | 235 ± 18.8 |
Maximum measured concentration of Metformin in plasma (Cmax) is presented
| ng/mL | FDC 25 Fed (T1) | E25+L5+M1000 Fed (R1) | FDC 25 Fast (T2) | E25+L5+M1000 Fast (R2) | FDC 10 Fed (T3) | E10+L5+M1000 Fed (R3) |
|---|---|---|---|---|---|---|
| Maximum Measured Concentration of Metformin in Plasma (Cmax) | 1290 ± 25.0 | 1300 ± 21.4 | 1010 ± 31.1 | 1020 ± 32.8 | 1170 ± 33.3 | 1150 ± 32.6 |
Maximum measured concentration of Linagliptin in plasma (Cmax) is presented
| nmol/L | FDC 25 Fed (T1) | E25+L5+M1000 Fed (R1) | FDC 25 Fast (T2) | E25+L5+M1000 Fast (R2) | FDC 10 Fed (T3) | E10+L5+M1000 Fed (R3) |
|---|---|---|---|---|---|---|
| Maximum Measured Concentration of Linagliptin in Plasma (Cmax) | 6.37 ± 20.6 | 6.51 ± 19.4 | 9.66 ± 44.5 | 8.35 ± 27.2 | 6.25 ± 23.1 | 6.15 ± 22.8 |
Area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72) is presented
| nmol*h/L | FDC 25 Fed (T1) | E25+L5+M1000 Fed (R1) | FDC 25 Fast (T2) | E25+L5+M1000 Fast (R2) | FDC 10 Fed (T3) | E10+L5+M1000 Fed (R3) |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) | 273 ± 18.7 | 282 ± 17.2 | 290 ± 24.7 | 276 ± 21.1 | 258 ± 25.1 | 260 ± 20.2 |
Area under the concentration-time curve of the Empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented
| nmol*h/L | FDC 25 Fed (T1) | E25+L5+M1000 Fed (R1) | FDC 25 Fast (T2) | E25+L5+M1000 Fast (R2) | FDC 10 Fed (T3) | E10+L5+M1000 Fed (R3) |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 6060 ± 25.7 | 6190 ± 22.5 | 6490 ± 20.0 | 6300 ± 18.7 | 2130 ± 15.5 | 2180 ± 15.4 |
Area under the concentration-time curve of the Metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented
| ng*h/mL | FDC 25 Fed (T1) | E25+L5+M1000 Fed (R1) | FDC 25 Fast (T2) | E25+L5+M1000 Fast (R2) | FDC 10 Fed (T3) | E10+L5+M1000 Fed (R3) |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 14100 ± 29.3 | 14100 ± 30.0 | 8260 ± 29.2 | 8600 ± 33.2 | 12200 ± 25.8 | 12400 ± 25.0 |
Area under the concentration-time curve of the Linagliptin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented
| nmol*h/L | FDC 25 Fed (T1) | E25+L5+M1000 Fed (R1) | FDC 25 Fast (T2) | E25+L5+M1000 Fast (R2) | FDC 10 Fed (T3) | E10+L5+M1000 Fed (R3) |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of the Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 465 ± 27.2 | 483 ± 24.8 | 477 ± 31.1 | 443 ± 25.2 | 424 ± 27.6 | 420 ± 27.1 |
Collected over Adverse events occurring up to 168 hours after intake of trial drug administration in each treatment period were assigned to treatment. Adverse events were collected up to 42 days per participant.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FDC 25 Fed (T1) | — | 0/15 (0%) | 5/15 (33.3%) |
| E25+L5+M1000 Fed (R1) | — | 0/14 (0%) | 4/14 (28.6%) |
| FDC 25 Fast (T2) | — | 0/20 (0%) | 6/20 (30%) |
| E25+L5+M1000 Fast (R2) | — | 0/18 (0%) | 4/18 (22.2%) |
| FDC 10 Fed (T3) | — | 0/14 (0%) | 1/14 (7.1%) |
| E10+L5+M1000 Fed (R3) | — | 0/15 (0%) | 4/15 (26.7%) |
| Event | FDC 25 Fed (T1) | E25+L5+M1000 Fed (R1) | FDC 25 Fast (T2) | E25+L5+M1000 Fast (R2) | FDC 10 Fed (T3) | E10+L5+M1000 Fed (R3) |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/15 | 2/14 | 3/20 | 3/18 | 1/14 | 2/15 |
| NauseaGastrointestinal disorders | 1/15 | 2/14 | 1/20 | 0/18 | 0/14 | 2/15 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 0/14 | 0/20 | 1/18 | 0/14 | 2/15 |
| DizzinessNervous system disorders | 1/15 | 1/14 | 1/20 | 0/18 | 0/14 | 1/15 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/15 | 1/14 | 0/20 | 0/18 | 0/14 | 0/15 |
| Blister ruptureSkin and subcutaneous tissue disorders | 0/15 | 1/14 | 0/20 | 0/18 | 0/14 | 0/15 |
| Abdominal pain upperGastrointestinal disorders | 0/15 | 0/14 | 1/20 | 0/18 | 0/14 | 1/15 |
| VomitingGastrointestinal disorders | 1/15 | 0/14 | 0/20 | 0/18 | 0/14 | 0/15 |
| Decreased appetiteMetabolism and nutrition disorders | 0/15 | 0/14 | 0/20 | 0/18 | 0/14 | 1/15 |
| NasopharyngitisInfections and infestations | 0/15 | 0/14 | 0/20 | 1/18 | 0/14 | 0/15 |
Treated set (TS): This subject set included all randomised subjects, whether treated or not, who were documented to have received at least 1 dose of study drug. This is the full analysis set population in the sense of ICH E9.
| Age, Continuous(years) | FDC 25 Fed (T1)/ E25+L5+M1000 Fed (R1) (Part 1) | E25+L5+M1000 Fed (R1)/ FDC 25 Fed (T1) (Part 1) | FDC 25 Fast (T2)/ E25+L5+M1000 Fast (R2) (Part 2) | E25+L5+M1000 Fast (R2)/ FDC 25 Fast (T2) (Part 2) | FDC 10 Fed (T3)/ E10+L5+M1000 Fed (R3) (Part 3) | E10+L5+M1000 Fed (R3)/ FDC 10 Fed (T3) (Part 3) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 36.7 ± 8.9 | 37.1 ± 11.9 | 36.2 ± 12.3 | 34.1 ± 10.0 | 37.3 ± 11.9 | 35.3 ± 9.4 | 36.0 ± 10.4 |
| Sex: Female, Male(Participants) | FDC 25 Fed (T1)/ E25+L5+M1000 Fed (R1) (Part 1) | E25+L5+M1000 Fed (R1)/ FDC 25 Fed (T1) (Part 1) | FDC 25 Fast (T2)/ E25+L5+M1000 Fast (R2) (Part 2) | E25+L5+M1000 Fast (R2)/ FDC 25 Fast (T2) (Part 2) | FDC 10 Fed (T3)/ E10+L5+M1000 Fed (R3) (Part 3) | E10+L5+M1000 Fed (R3)/ FDC 10 Fed (T3) (Part 3) | Total |
|---|---|---|---|---|---|---|---|
| Female | 3 | 4 | 7 | 2 | 4 | 1 | 21 |
| Male | 4 | 4 | 3 | 8 | 3 | 7 | 29 |
Ran from Jul 2016 to primary completion in Oct 2016, 2 months.
Results were first posted in Feb 2020, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.